Stock SCPH SCPHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages scPharmaceuticals Inc.

Equities

SCPH

US8106481059

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
4.54 USD +1.57% Intraday chart for scPharmaceuticals Inc. +0.89% -27.59%
24/04 ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection CI
13/03 Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
ScPharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
ScPharmaceuticals Expects Higher Q4 Product Sales
ScPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth Initiatives
ScPharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
ScPharmaceuticals Receives Positive FDA Feedback on Potential Heart Failure Class IV Indication Expansion for Furoscix
ScPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion
ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
ScPharmaceuticals Inc. Announces Launch and Commercial Availability of FUROSCIX® (Furosemide Injection)
ScPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
ScPharmaceuticals Names Rachael Nokes as CFO
ScPharmaceuticals Expects to Raise $50 Million From Public Offering; Shares Gain
ScPharmaceuticals to Launch Common Stock Offering
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
ScPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCPH Stock
  4. News scPharmaceuticals Inc.
  5. Other languages